Literature DB >> 2849672

R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine.

J F Kachur1, J S Peterson, J P Carter, W J Rzeszotarski, R C Hanson, L Noronha-Blob.   

Abstract

Oxybutynin (Ditropan) is widely utilized in treatment of incontinence due to neurogenic bladder dysfunction. We prepared its R and S enantiomers and evaluated their antimuscarinic, Ca++-channel antagonistic and spasmolytic effects in guinea pig detrusor strips and ileal longitudinal muscle. Ussing chambers were used to assess inhibition of carbachol-induced mucosal Cl-secretion in vitro. The enantiomers and the racemate were also tested in in vivo preparations for local anesthetic activity and for antimuscarinic activity in the slow filling cystometrogram. Stereoselective antimuscarinic effects [R)OXY:(R/S)OXY:(S)OXY) were evident for isolated ileal longitudinal (0.12:1.0:4.5) and bladder detrusor muscle (0.5:1.0:13) isolated ileal mucosa (0.2:1:8.9) and acetylcholine stimulated phosphoinositide turn-over in vitro (0.24:1.0:39). Stereoselectivity was also evident for the volume-induced contractions of the cystometrogram in vivo (0.7:1:15). In contrast, no stereoselectivity was observed for Ca++-channel antagonism, spasmolytic and local anesthetic properties of (R/S)OXY and its enantiomers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849672

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

Review 2.  Oxybutynin: past, present, and future.

Authors:  Kelly Jirschele; Peter K Sand
Journal:  Int Urogynecol J       Date:  2012-09-14       Impact factor: 2.894

3.  Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.

Authors:  R H Zobrist; B Schmid; A Feick; D Quan; S W Sanders
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

Review 4.  Contemporary and emerging drug treatments for urinary incontinence in children.

Authors:  Mitchell R Humphreys; Yuri E Reinberg
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  Pharmacotherapy for nocturia in the elderly patient.

Authors:  Ragnar Asplund
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.

Authors:  H Matsuo; A Matsui; R Nasu; H Takanaga; N Inoue; F Hattori; H Ohtani; Y Sawada
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

7.  Oxybutynin extended-release: a review of its use in the management of overactive bladder.

Authors:  M Asif A Siddiqui; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Transdermal oxybutynin: for overactive bladder.

Authors:  Lynne M Bang; Stephanie E Easthope; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors.

Authors:  Elfaridah P Frazier; Stephan L M Peters; Alan S Braverman; Michael R Ruggieri; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-04       Impact factor: 3.000

10.  Oxybutynin extended release for the management of overactive bladder: a clinical review.

Authors:  A M Arisco; E K Brantly; S R Kraus
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.